Bristol-Myers Squibb Co (NYSE:BMY) Shares Purchased by Altium Wealth Management LLC

Altium Wealth Management LLC raised its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 103.5% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 16,289 shares of the biopharmaceutical company’s stock after buying an additional 8,285 shares during the quarter. Altium Wealth Management LLC’s holdings in Bristol-Myers Squibb were worth $1,046,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Schroder Investment Management Group increased its position in Bristol-Myers Squibb by 6.1% during the second quarter. Schroder Investment Management Group now owns 4,690,132 shares of the biopharmaceutical company’s stock worth $212,698,000 after buying an additional 270,185 shares during the period. ETF Managers Group LLC increased its position in Bristol-Myers Squibb by 78.4% during the second quarter. ETF Managers Group LLC now owns 4,095 shares of the biopharmaceutical company’s stock worth $185,000 after buying an additional 1,799 shares during the period. Mackenzie Financial Corp increased its position in Bristol-Myers Squibb by 13.5% during the second quarter. Mackenzie Financial Corp now owns 261,863 shares of the biopharmaceutical company’s stock worth $11,875,000 after buying an additional 31,096 shares during the period. Zebra Capital Management LLC acquired a new position in Bristol-Myers Squibb during the second quarter worth approximately $237,000. Finally, Beacon Pointe Advisors LLC increased its position in Bristol-Myers Squibb by 13.2% during the second quarter. Beacon Pointe Advisors LLC now owns 8,133 shares of the biopharmaceutical company’s stock worth $368,000 after buying an additional 947 shares during the period. 83.02% of the stock is owned by institutional investors.

Shares of Bristol-Myers Squibb stock traded up $0.33 during trading on Friday, reaching $67.11. The company’s stock had a trading volume of 200,779 shares, compared to its average volume of 15,257,604. The company has a quick ratio of 3.72, a current ratio of 3.83 and a debt-to-equity ratio of 1.37. Bristol-Myers Squibb Co has a 12-month low of $42.48 and a 12-month high of $67.09. The company has a market capitalization of $108.25 billion, a P/E ratio of 16.86, a price-to-earnings-growth ratio of 0.85 and a beta of 0.73. The business has a 50 day moving average price of $62.71 and a 200-day moving average price of $53.14.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.17 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.06 by $0.11. Bristol-Myers Squibb had a return on equity of 45.49% and a net margin of 23.53%. The firm had revenue of $6.01 billion for the quarter, compared to the consensus estimate of $5.89 billion. During the same period in the previous year, the business earned $1.09 earnings per share. The company’s revenue for the quarter was up 5.6% compared to the same quarter last year. Research analysts predict that Bristol-Myers Squibb Co will post 4.47 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, February 3rd. Investors of record on Friday, January 3rd will be paid a $0.45 dividend. The ex-dividend date of this dividend is Thursday, January 2nd. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.41. This represents a $1.80 dividend on an annualized basis and a dividend yield of 2.68%. Bristol-Myers Squibb’s payout ratio is 45.23%.

BMY has been the topic of several research analyst reports. Argus raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $80.00 price target on the stock in a research report on Friday, December 13th. Morgan Stanley started coverage on Bristol-Myers Squibb in a research report on Friday, November 22nd. They set an “equal weight” rating and a $60.00 price target on the stock. Wolfe Research set a $66.00 target price on Bristol-Myers Squibb and gave the company a “buy” rating in a report on Friday, November 1st. William Blair reissued a “buy” rating on shares of Bristol-Myers Squibb in a report on Friday, December 13th. Finally, Bank of America started coverage on Bristol-Myers Squibb in a report on Wednesday, October 16th. They issued a “buy” rating and a $60.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and thirteen have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $61.69.

In related news, SVP John E. Elicker sold 15,000 shares of Bristol-Myers Squibb stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $56.66, for a total value of $849,900.00. Following the sale, the senior vice president now directly owns 74,471 shares in the company, valued at $4,219,526.86. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Louis S. Schmukler sold 25,000 shares of Bristol-Myers Squibb stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $56.56, for a total value of $1,414,000.00. Following the completion of the sale, the insider now owns 31,963 shares in the company, valued at $1,807,827.28. The disclosure for this sale can be found here. 0.13% of the stock is owned by insiders.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

See Also: Resistance Level

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.